Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Current Opinion in Pharmacology|December 10, 2016
Biased mu-opioid receptor ligands: a promising new generation of pain therapeuticsEdward R Siuda, Richard Carr, David H Rominger, et al.Current Opinion in Pharmacology|May 20, 2014
Biased ligands: pathway validation for novel GPCR therapeuticsDavid H Rominger, Conrad L Cowan, William Gowen-MacDonald, et al.Molecular Pharmacology|May 26, 2011
Quantifying ligand bias at seven-transmembrane receptorsSudarshan Rajagopal, Seungkirl Ahn, David H Rominger, et al.The Journal of Pharmacology and Experimental Therapeutics|August 31, 2010
Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performanceJonathan D Violin, Scott M DeWire, Dennis Yamashita, et al.The Journal of Pharmacology and Experimental Therapeutics|May 24, 2017
TRV0109101, a G Protein-Biased Agonist of the µ-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic AdministrationMichael Koblish, Richard Carr, Edward R Siuda, et al.The Journal of Biological Chemistry|March 27, 2014
Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR)Ryan T Strachan, Jin-peng Sun, David H Rominger, et al.Journal of Medicinal Chemistry|September 26, 2013
Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe painXiao-Tao Chen, Philip Pitis, Guodong Liu, et al.The Journal of Pharmacology and Experimental Therapeutics|March 22, 2003
Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptorsGe Zhang, Ning Huang, Yu-Wen Li, et al.The Journal of Pharmacology and Experimental Therapeutics|January 10, 2013
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphineScott M DeWire, Dennis S Yamashita, David H Rominger, et al.The Journal of Pharmacology and Experimental Therapeutics|March 24, 2009
Evidence for allosteric interactions of antagonist binding to the smoothened receptorCynthia M Rominger, Wei-Lin Tiger Bee, Robert A Copeland, et al.Pageof 1